Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.79 |
| ▸ | HPGD | P15428 | 5/20 | 0.79 |
| ▸ | GAA | P10253 | 5/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.60 |
| ▸ | GAPDH | P04406 | 1/20 | 0.59 |
| ▸ | MGAM | O43451 | 1/20 | 0.57 |
| ▸ | SI | P14410 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Marmesin SCHEMBL30977125 | 1.00 | ACHE (1.00) | ACHENPC1ALDH1A1HPGDGAA | |
| Marmesin SCHEMBL546574 | 1.00 | ACHE (1.00) | ACHENPC1ALDH1A1HPGDGAA | |
| Marmesin SCHEMBL29471037 | 1.00 | ACHE (1.00) | ACHENPC1ALDH1A1HPGDGAA | |
| Marmesin SCHEMBL503874 | 0.93 | ACHE (0.86) | ACHENPC1ALDH1A1HPGDGAA | |
| Marmesin Acetate SCHEMBL2257271 | 0.85 | ALDH1A1 (1.00) | ACHENPC1ALDH1A1HPGDGAA | |
| Marmesin Acetate SCHEMBL12062110 | 0.85 | ALDH1A1 (1.00) | ACHENPC1ALDH1A1HPGDGAA | |
| Felamidin SCHEMBL30467160 | 0.81 | ALDH1A1 (0.75) | ACHENPC1ALDH1A1HPGDGAA | |
| (-)-Prantschimgin SCHEMBL13337338 | 0.81 | ALDH1A1 (0.78) | ACHENPC1ALDH1A1HPGDGAA | |
| Felamidin SCHEMBL12062114 | 0.81 | ALDH1A1 (0.75) | ACHENPC1ALDH1A1HPGDGAA | |
| SCHEMBL30777266 | 0.78 | ALDH1A1 (0.71) | ACHENPC1ALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118339274-A | Brandy replica | 艾娃食品实验室股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-117437980-A | Screening method of core genes acting on chronic pelvic inflammatory disease by using gongyan-Ping | 广东罗浮山国药股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| WO-2023233094-A1 | FUSION PROTEIN AND USE FOR BIOVCONVERTING MOLECULES | UNIVERSITE DE LORRAINE (FR) | 2023-12-07 | — | — | WO | disclosed |
| US-8772252-B2 | Coumarin compounds as melanogenesis modifiers and uses thereof | NEW YORK UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772252-B2 | Coumarin compounds as melanogenesis modifiers and uses thereof | NEW YORK UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8563754-B2 | Compounds, compositions and methods for preventing skin darkening | NEW YORK UNIVERSITY (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563754-B2 | Compounds, compositions and methods for preventing skin darkening | NEW YORK UNIVERSITY (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120220545-A1 | COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | NEW YORK UNIVERSITY | 2012-08-30 | — | — | US | disclosed |
| US-20120220545-A1 | COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | NEW YORK UNIVERSITY | 2012-08-30 | — | — | US | disclosed |
| WO-2011094016-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING | NEW YORK UNIVERSITY (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110190229-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING | NEW YORK UNIVERSITY | 2011-08-04 | — | — | US | disclosed |
| US-20110190229-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING | NEW YORK UNIVERSITY | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220545-A1 | COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | TYR, MC1R, MITF | ACHE 1318/4885NPC1 1577/4885ALDH1A1 246/4885 |
| US-20110190229-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING | TYR, MC1R, MITF | ACHE 238/4885NPC1 2645/4885ALDH1A1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.